Get the Stockscreener App
3.29
7.32%
-0.26
Skye Bioscience Inc stock is traded at $3.29, with a volume of 487.56K.
It is down -7.32% in the last 24 hours and down -15.21% over the past month.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
See More
Previous Close:
$3.55
Open:
$3.61
24h Volume:
487.56K
Relative Volume:
0.57
Market Cap:
$101.95M
Revenue:
-
Net Income/Loss:
$-21.24M
P/E Ratio:
-3.9265
EPS:
-0.8379
Net Cash Flow:
$-22.47M
1W Performance:
-6.27%
1M Performance:
-15.21%
6M Performance:
+10.40%
1Y Performance:
-37.69%
1-Day Range:
$3.27
$3.6194
1-Week Range:
$3.23
$3.7498
52-Week Range:
$1.14
$7.47
Skye Bioscience Inc Stock (SKYE) Company Profile
Name
Skye Bioscience Inc
Sector
Industry
Phone
(858) 410-0266
Address
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Compare SKYE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
0.92 | 1.26B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.58 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.53 | 110.24M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1668 | 351.80M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.24 | 0 | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Initiated | Evercore ISI | Outperform |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Sep-30-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-10-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-09-24 | Initiated | Craig Hallum | Buy |
| May-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-24 | Initiated | Oppenheimer | Outperform |
View All
Skye Bioscience Inc Stock (SKYE) Latest News
Skye Bioscience (NASDAQ:SKYE) Upgraded at Evercore ISI - MarketBeat
Altium Capital Management LLC Trims Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - MarketBeat
Will Skye Bioscience Inc. Bounce From 52 Week LowJuly 2025 Summary & Expert Curated Trade Ideas - 선데이타임즈
Skye Bioscience's Nimacimab: A New Frontier in Obesity Treatment and a Strategic Buy Opportunity - AInvest
Skye initiated at overweight at Evercore on obesity asset nimacimab - MSN
Evercore ISI Group initiates Skye Bioscience coverage with Outperform, $10 PT. - AInvest
Skye Bioscience Earnings Call: Positive Outlook Amid Challenges - MSN
Evercore Initiates SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Announces Target Price $10 - 富途牛牛
Evercore starts Skye Bioscience at Outperform on nimacimab potential - MSN
Will Skye Bioscience Inc. Hold Gains Into CloseLong Setup & Free Accurate Trade Setup Notifications - kangso.co.kr
Live Scanner Shows Breakout on Skye Bioscience Inc.July 2025 Spike Watch & High Yield Equity Trading Tips - newsyoung.net
Craig-Hallum Sticks to Their Buy Rating for Skye Bioscience (SKYE) - The Globe and Mail
Why Skye Bioscience Inc. stock attracts strong analyst attentionValue Into Profit Opportunities - sisaissue.com
Craig-Hallum Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating - 富途牛牛
Skye Bioscience's 2025Q2 Earnings Call: Unraveling Key Contradictions in Clinical Trial Insights and Drug Efficacy - AInvest
Skye Bioscience Q2 2025 slides: Nimacimab targets obesity treatment gaps By Investing.com - Investing.com Nigeria
Skye Bioscience signals late Q3/early Q4 top-line Phase IIa results as nimacimab advances obesity treatment platform - MSN
Skye Bioscience Q2 2025 slides: Nimacimab targets obesity treatment gaps - Investing.com India
Oppenheimer Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $17 - 富途牛牛
Piper Sandler Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛
Skye Bioscience Inc (SKYE) Q2 2025 Earnings Call Highlights: Promising Trial Progress Amid ... - Yahoo Finance
Skye Bioscience Inc (SKYE) Q2 2025 Earnings Call Highlights: Promising Trial Progress Amid ... By GuruFocus - Investing.com Canada
Earnings call transcript: Skye Bioscience Q2 2025 sees R&D surge, stock dips - Investing.com Australia
Skye Bioscience shares rise 6.48% premarket after Q2 2025 earnings call. - AInvest
Skye Bioscience Releases Q2 2025 Financial Results - TipRanks
William Blair Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating - 富途牛牛
Skye Bioscience Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Transcript : Skye Bioscience, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update - The Manila Times
Skye Bioscience : Corporate Presentation (250807 Skye Investor Deck) - MarketScreener
Skye Bioscience Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Skye Bioscience SKYE 2025Q2 Earnings Preview Upside Potential Driven by Analyst Forecasts - AInvest
We Think Skye Bioscience (NASDAQ:SKYE) Needs To Drive Business Growth Carefully - Yahoo Finance
What makes Skye Bioscience Inc. stock price move sharplyBuild a balanced portfolio for long-term success - Jammu Links News
How volatile is Skye Bioscience Inc. stock compared to the marketSky-high return potential - Jammu Links News
Is Skye Bioscience Inc. a good long term investmentMaximize gains with proven stock analysis - Jammu Links News
What drives Skye Bioscience Inc. stock priceAchieve rapid wealth accumulation through smart investing - Jammu Links News
What are analysts’ price targets for Skye Bioscience Inc. in the next 12 monthsUnlock powerful portfolio management tools - Jammu Links News
Skye Bioscience Shares Are Trading Higher After the Company Announced the Debut of Its "Anatomy of Progress" Nimacimab Development Update Video Series and Availability of Presentations Related to the Development of Its Anti-obesity Drug, Nimacimab - 富途牛牛
Why is Skye Bioscience Inc. stock attracting strong analyst attentionCapitalize on emerging trends for profits - Jammu Links News
What is the risk reward ratio of investing in Skye Bioscience Inc. stockGet daily expert analysis for smarter investing - Jammu Links News
Is Skye Bioscience Inc. stock overvalued or undervaluedAchieve consistent profits with expert advice - Jammu Links News
Is it the right time to buy Skye Bioscience Inc. stockMaximize portfolio value with smart investment plans - Jammu Links News
When is Skye Bioscience Inc. stock expected to show significant growthFree Stock Selection - Jammu Links News
How does Skye Bioscience Inc. compare to its industry peersAchieve breakthrough performance with smart picks - Jammu Links News
Should I hold or sell Skye Bioscience Inc. stock in 2025Build a strong portfolio for long-term success - Jammu Links News
Is Skye Bioscience Inc. a growth stock or a value stockHarness the power of proven investment plans - Jammu Links News
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Skye Bioscience Inc Stock (SKYE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Skye Bioscience Inc Stock (SKYE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schwab Andrew J. | Director |
Aug 21 '25 |
Sale |
3.57 |
60,956 |
217,613 |
63,963 |
| 5AM Partners VII, LLC | 10% Owner |
Aug 22 '25 |
Sale |
3.42 |
170,449 |
582,936 |
57,493 |
| 5AM Partners VII, LLC | 10% Owner |
Aug 21 '25 |
Sale |
3.57 |
60,956 |
217,613 |
63,963 |
| Diep Tuan Tu | Chief Development Officer |
Nov 18 '24 |
Sale |
4.99 |
19,489 |
97,250 |
82,259 |
| Diep Tuan Tu | Chief Development Officer |
Nov 15 '24 |
Sale |
5.55 |
85 |
472 |
101,748 |
| ARSENAULT KAITLYN | Chief Financial Officer |
Nov 18 '24 |
Sale |
4.99 |
43,206 |
215,598 |
166,342 |
| ARSENAULT KAITLYN | Chief Financial Officer |
Nov 15 '24 |
Sale |
5.55 |
190 |
1,054 |
209,548 |
| DHILLON PUNIT | Chief Executive Officer |
Nov 18 '24 |
Sale |
4.99 |
82,546 |
411,905 |
329,823 |
| DHILLON PUNIT | Chief Executive Officer |
Nov 15 '24 |
Sale |
5.55 |
364 |
2,020 |
412,369 |
| Grayson Paul A. | Director |
Nov 18 '24 |
Sale |
4.99 |
86,244 |
430,358 |
259,701 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):